CorMedix Inc.(CRMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CRMD CorMedix Inc.

Trading 08-06 15:34:25 EDT

7.46

+0.05

+0.61%

High7.52	Low7.39	Vol381.59K
Open7.43	D1 Closing7.41	Amplitude1.75%
Mkt Cap587.37M	Tradable Cap496.00M	Total Shares78.79M
T/O2.85M	T/O Rate0.57%	Tradable Shares66.53M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CRMD","market":"US","secType":"STK","nameCN":"CorMedix Inc.","latestPrice":7.455,"timestamp":1786044864138,"preClose":7.41,"halted":0,"volume":381587,"delay":0,"changeRate":0.006072874493927116,"floatShares":66531899,"shares":78789045,"eps":2.11996,"marketStatus":"Trading","change":0.045,"latestTime":"08-06 15:34:25 EDT","open":7.43,"high":7.52,"low":7.39,"amount":2848401.570353,"amplitude":0.017544,"askPrice":7.46,"askSize":336,"bidPrice":7.45,"bidSize":232,"shortable":3,"etf":0,"ttmEps":2.11996,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1786046400000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1273723200000,"exchange":"NASDAQ","adjPreClose":7.41,"preHourTrading":{"tag":"盘前","latestPrice":7.41,"preClose":7.41,"latestTime":"09:28 EDT","volume":113,"amount":836.127002,"timestamp":1786022901034,"change":0,"changeRate":0,"amplitude":0.08502},"postHourTrading":{"tag":"盘后","latestPrice":7.45,"preClose":7.41,"latestTime":"19:34 EDT","volume":21153,"amount":157087.8825,"timestamp":1785972849789,"change":0.04,"changeRate":0.005398,"amplitude":0.018893},"volumeRatio":0.516887,"impliedVol":0.7805,"impliedVolPercentile":0.7291},"requestUrl":"/m/hq/s/CRMD","defaultTab":"news","newsList":[{"id":"2655898342","title":"CorMedix to Report Q2 Results, Host Corporate Update Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2655898342","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655898342?lang=en_us&edition=fundamental","pubTime":"2026-07-29 20:33","pubTimestamp":1785328381,"startTime":"0","endTime":"0","summary":"CorMedix to report Q2 results, host corporate update callCorMedix will report second-quarter 2026 results before the market opens on Aug. 13, 2026.A corporate update conference call is scheduled for A","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nNDLxZq6S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","SG9999014013.SGD","LU0314104364.USD","SG9999014021.USD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","LU2095319765.USD","BCDF","NDAQ","BK4588","IE00BN0W2W23.USD","SG9999014005.SGD","IE00BN0W2T93.GBP","CRMD","BK4007","IE00BN0W2V16.EUR","BK4112","LU2210149790.SGD","IE00BKPKM429.USD","LU2210150020.SGD","SG9999014039.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655003860","title":"CorMedix Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 13, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2655003860","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655003860?lang=en_us&edition=fundamental","pubTime":"2026-07-29 20:30","pubTimestamp":1785328201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nTUA7BQ7DL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CRMD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648336866","title":"Cormedix Names Elizabeth Hurlburt Chief Operating and Commercial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2648336866","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648336866?lang=en_us&edition=fundamental","pubTime":"2026-07-03 04:33","pubTimestamp":1783024391,"startTime":"0","endTime":"0","summary":"CorMedix names Elizabeth Hurlburt chief operating and commercial officerCorMedix reshaped its executive structure on June 29, 2026, naming COO Elizabeth Hurlburt to a new Chief Operating and Commercia","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260702:nNDL3xGBG5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CRMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648517115","title":"Cormedix Switches Auditor, Names Ernst & Young for 2026 Audit","url":"https://stock-news.laohu8.com/highlight/detail?id=2648517115","media":"Reuters","labels":["executive","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648517115?lang=en_us&edition=fundamental","pubTime":"2026-07-01 19:14","pubTimestamp":1782904490,"startTime":"0","endTime":"0","summary":"CorMedix switches auditor, names Ernst & Young for 2026 auditCorMedix replaced CBIZ CPAs with Ernst & Young as independent auditor for fiscal 2026, effective June 25, 2026.Audit reports for fiscal 202","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260701:nNDLxSl2Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRMD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646802846","title":"Cormedix Holds Annual Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2646802846","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646802846?lang=en_us&edition=fundamental","pubTime":"2026-06-25 04:34","pubTimestamp":1782333296,"startTime":"0","endTime":"0","summary":"CorMedix holds annual shareholder meetingCorMedix held its annual shareholder meeting on June 23, 2026.Shareholders ratified the appointment of CBIZ CPAs P.C. as independent registered public accounti","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nNDL3QJrVJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRMD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644725028","title":"Raised 2026 Guidance and DefenCath Momentum Might Change The Case For Investing In CorMedix (CRMD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2644725028","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644725028?lang=en_us&edition=fundamental","pubTime":"2026-06-18 02:37","pubTimestamp":1781721455,"startTime":"0","endTime":"0","summary":"Earlier in 2026, CorMedix Inc. reported strong Q1 results driven by DefenCath and raised its full-year 2026 guidance while outlining progress on late-stage programs such as REZZAYO.\nManagement also emphasized continued business momentum even as the company prepares for the expiration of temporary TDAPA reimbursement, highlighting execution in a changing reimbursement backdrop.\nNext, we will examine how CorMedix's raised 2026 guidance and DefenCath’s contribution shape the company’s broader...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crmd/cormedix/news/raised-2026-guidance-and-defencath-momentum-might-change-the","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crmd/cormedix/news/raised-2026-guidance-and-defencath-momentum-might-change-the","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","CRMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641482390","title":"CorMedix announces United States Court of Appeals affirms patent judgements","url":"https://stock-news.laohu8.com/highlight/detail?id=2641482390","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641482390?lang=en_us&edition=fundamental","pubTime":"2026-06-08 21:00","pubTimestamp":1780923611,"startTime":"0","endTime":"0","summary":"CorMedix (CRMD) announced that the United States Court of Appeals for the Federal Circuit has affirmed the judgment of the U.S. District Court for ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cormedix-announces-united-states-court-of-appeals-affirms-patent-judgements-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cormedix-announces-united-states-court-of-appeals-affirms-patent-judgements-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["US12M.BOND","US6M.BOND","CRMD","TMF","US2Y.BOND","US30Y.BOND","US7Y.BOND","UBCP","TLTW","US3Y.BOND","US5Y.BOND","US10Y.BOND","TLT","BK4007","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641844924","title":"Federal Circuit upholds CorMedix win in MINOCIN patent case against Nexus","url":"https://stock-news.laohu8.com/highlight/detail?id=2641844924","media":"Reuters","labels":["corporation","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641844924?lang=en_us&edition=fundamental","pubTime":"2026-06-08 20:46","pubTimestamp":1780922766,"startTime":"0","endTime":"0","summary":"CorMedix won a Federal Circuit ruling affirming MINOCIN for Injection patents as valid, rejecting Nexus Pharmaceuticals’ invalidity challenge.The court upheld findings that Nexus’ proposed generic minocycline infringes the Orange Book-listed patents.A permanent injunction barring Nexus from marketing its generic before patent expiration was affirmed.The decision leaves CorMedix’s MINOCIN franchise protected from early generic entry.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CorMedix Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 08, 2026, and is solely responsible for the ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nNDL6FkvsM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRMD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641843024","title":"U.S. Court of Appeals for the Federal Circuit Affirms Victory for CorMedix Therapeutics in Minocin® Patent Litigation","url":"https://stock-news.laohu8.com/highlight/detail?id=2641843024","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641843024?lang=en_us&edition=fundamental","pubTime":"2026-06-08 20:32","pubTimestamp":1780921957,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nFWN42G0XK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CRMD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641550484","title":"CorMedix - Federal Circuit Affirms Minocin Patents Valid and Infringed by Nexus Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2641550484","media":"THOMSON REUTERS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641550484?lang=en_us&edition=fundamental","pubTime":"2026-06-08 20:32","pubTimestamp":1780921957,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nFWN42G0XK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CRMD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635082084","title":"CorMedix to join RBC Capital Markets Global Healthcare Conference fireside chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2635082084","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635082084?lang=en_us&edition=fundamental","pubTime":"2026-05-15 20:31","pubTimestamp":1778848298,"startTime":"0","endTime":"0","summary":"CorMedix to take part in fireside chat at RBC Capital Markets Global Healthcare Conference in New York on May 20, 2026 at 11:00 a.m. EDT.Management also scheduled for fireside chat at Jefferies Global Healthcare Conference in New York on June 3, 2026 at 4:20 p.m. EDT.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDLbWgcLB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","CRMD","SG9999014013.SGD","LU2095319765.USD","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","SG9999014021.USD","IE00BKPKM429.USD","LU0314104364.USD","BK4112","IE00B3QW5Z07.USD","LU2210149790.SGD","LU2210150020.SGD","IE00BN0W2V16.EUR","NDAQ","BK4007","IE00BGHQF748.EUR","SG9999014005.SGD","SG9999014039.USD","BK4588","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635508600","title":"RBC Capital Keeps Their Buy Rating on Cormedix (CRMD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635508600","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635508600?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:09","pubTimestamp":1778843379,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Leonid Timashev maintained a Buy rating on Cormedix yesterday and set a price target of $14.00. The company’s shares closed yes...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-keeps-their-buy-rating-on-cormedix-crmd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-keeps-their-buy-rating-on-cormedix-crmd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635747065","title":"CorMedix Shares Climb With Higher 1Q Profit, Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2635747065","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635747065?lang=en_us&edition=fundamental","pubTime":"2026-05-15 02:44","pubTimestamp":1778784240,"startTime":"0","endTime":"0","summary":"CorMedix shares rose after the company reported higher first-quarter profit and revenue.Shares of the biopharmaceutical company rose 8.5% on Thursday to $8.14. The company's shares are still down more than 30% year to date.The company on Thursday posted a first-quarter profit of $38.6 million, or 43 cents a share, compared with $20.6 million, or 30 cents a share, a year earlier. Analysts polled by FactSet expected 34 cents a share.Revenue rose to $127.4 million from $39.1 million in the year-ago quarter. Analysts expected $105 million. The company's sales increased largely due to the onboarding of a large dialysis organization in mid 2025, the company said. Sales of DefenCath, the company's catheter lock solution, contributed $97.5 million in revenue in the quarter.\"DefenCath continues to exceed expectations despite pending TDAPA expiration and demonstrates strong underlying utilization demand,\" said Chief Executive Joseph Todisco. \"In addition, we are advancing a pipeline of late-stag","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRMD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635747859","title":"Analysts Offer Insights on Healthcare Companies: Immatics (IMTX) and Cormedix (CRMD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635747859","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635747859?lang=en_us&edition=fundamental","pubTime":"2026-05-15 02:00","pubTimestamp":1778781628,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Immatics (IMTX) and Cormedix (CRMD) with bullish sen...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-immatics-imtx-and-cormedix-crmd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-immatics-imtx-and-cormedix-crmd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","LU0029874061.USD","XLV","IMTX","LABU","BK4581","BK4139","BK4137","BK4007","BK4588","LU0128526141.USD","XBI","CRMD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635748420","title":"CorMedix Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635748420","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635748420?lang=en_us&edition=fundamental","pubTime":"2026-05-14 21:31","pubTimestamp":1778765482,"startTime":"0","endTime":"0","summary":"CorMedix Inc reports results for the quarter ended March 31 - Earnings SummaryCorMedix Inc CRMD.OQ reported quarterly adjusted earnings of 49 cents per share for the quarter ended March 31, lower than","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nL8N41R1IB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CRMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635123877","title":"CorMedix Q1 net income rises to $38.6 million; revenue more than doubled to $127.4 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635123877","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635123877?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:01","pubTimestamp":1778760097,"startTime":"0","endTime":"0","summary":"CorMedix posted net income of USD 38.6 million, up 87% year over year, as revenue more than doubled to USD 127.43 million.Operating income climbed to USD 63.66 million, up 216%, while total operating expenses rose to USD 41.46 million, up 139%.Product sales increased to USD 121.92 million, up more than doubled, including DefenCath sales of USD 97.51 million; contract revenue was USD 5.51 million.Other expense totaled USD 8.01 million, reflecting USD 3.55 million unrealized loss on Talphera equity securities and USD 4.2 million change in contingent consideration.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CorMedix Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis,","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nNDL4flL8c:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CRMD","TLPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635671253","title":"CorMedix reports Q1 EPS 43c, consensus 33c","url":"https://stock-news.laohu8.com/highlight/detail?id=2635671253","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635671253?lang=en_us&edition=fundamental","pubTime":"2026-05-14 19:53","pubTimestamp":1778759631,"startTime":"0","endTime":"0","summary":"Reports Q1 revenue $127.43M, consensus $104.96M. Joseph Todisco, CorMedix (CRMD) chairman and CEO, commented, “CorMedix has entered 2026 with stron...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cormedix-reports-q1-eps-43c-consensus-33c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cormedix-reports-q1-eps-43c-consensus-33c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRMD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635575714","title":"CorMedix Q1 results beat on Defencath sales, raises outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2635575714","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635575714?lang=en_us&edition=fundamental","pubTime":"2026-05-14 19:40","pubTimestamp":1778758822,"startTime":"0","endTime":"0","summary":"CorMedix Q1 results beat on Defencath sales, raises outlookOverviewUS biopharma firm's Q1 revenue rose sharply, beating analyst expectationsAdjusted EPS for Q1 beat analyst expectationsCompany raised ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nL1N41R0JH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","LU0689626769.HKD","BK4149","LU0124676726.USD","LU0203345920.USD","BK4533","CMI","LU0154245673.USD","BK4007","CRMD","BK4567","LU0203347892.USD","LU0154245756.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635171487","title":"Cormedix Q1 Adj. EPS $0.43 Beats $0.36 Estimate, Sales $127.427M Beat $105.017M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2635171487","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635171487?lang=en_us&edition=fundamental","pubTime":"2026-05-14 19:33","pubTimestamp":1778758417,"startTime":"0","endTime":"0","summary":"Cormedix (NASDAQ:CRMD) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $0.36 by 16.22 percent. This is a 43.33 percent increase over earnings of $0.30 per share from the same","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52555383/cormedix-q1-adj-eps-0-43-beats-0-36-estimate-sales-127-427m-beat-105-017m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CRMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635711711","title":"CorMedix Inc - Raises FY 2026 Net Revenue Guidance to $325-$345 Mln; Adj Ebitda to $115-$135 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2635711711","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635711711?lang=en_us&edition=fundamental","pubTime":"2026-05-14 19:30","pubTimestamp":1778758203,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nTUA6GTLHX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CRMD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cormedix.com","stockEarnings":[{"period":"1week","weight":0.0306},{"period":"1month","weight":-0.157},{"period":"3month","weight":-0.0644},{"period":"6month","weight":-0.0364},{"period":"1year","weight":-0.3853},{"period":"ytd","weight":-0.3629}],"compareEarnings":[{"period":"1week","weight":0.0553},{"period":"1month","weight":0.0246},{"period":"3month","weight":0.0522},{"period":"6month","weight":0.1146},{"period":"1year","weight":0.2258},{"period":"ytd","weight":0.1289}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.133293},{"month":2,"riseRate":0.5,"avgChangeRate":0.066552},{"month":3,"riseRate":0.5,"avgChangeRate":0.041342},{"month":4,"riseRate":0.5,"avgChangeRate":-0.005656},{"month":5,"riseRate":0.25,"avgChangeRate":-0.108379},{"month":6,"riseRate":0.529412,"avgChangeRate":0.045878},{"month":7,"riseRate":0.411765,"avgChangeRate":0.049729},{"month":8,"riseRate":0.529412,"avgChangeRate":0.022933},{"month":9,"riseRate":0.375,"avgChangeRate":0.027376},{"month":10,"riseRate":0.4375,"avgChangeRate":0.043001},{"month":11,"riseRate":0.4375,"avgChangeRate":0.046811},{"month":12,"riseRate":0.4375,"avgChangeRate":0.057824}],"exchange":"NASDAQ","name":"CorMedix Inc.","nameEN":"CorMedix Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CorMedix Inc.(CRMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CorMedix Inc.(CRMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CorMedix Inc.,CRMD,CorMedix Inc.股票,CorMedix Inc.股票老虎,CorMedix Inc.股票老虎国际,CorMedix Inc.行情,CorMedix Inc.股票行情,CorMedix Inc.股价,CorMedix Inc.股市,CorMedix Inc.股票价格,CorMedix Inc.股票交易,CorMedix Inc.股票购买,CorMedix Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CorMedix Inc.(CRMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CorMedix Inc.(CRMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction